about
Prediction of "hot spots" of aggregation in disease-linked polypeptidesStructure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysisAnalysis of a new crystal form of procarboxypeptidase B: further insights into the catalytic mechanismA functional and structural study of the major metalloprotease secreted by the pathogenic fungus Aspergillus fumigatusAmyloid fibril formation by a partially structured intermediate state of alpha-chymotrypsin.Self-assembly of human latexin into amyloid-like oligomers.Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity.Dissecting the contribution of Staphylococcus aureus α-phenol-soluble modulins to biofilm amyloid structure.Understanding and predicting protein misfolding and aggregation: Insights from proteomics.Advances in the prediction of protein aggregation propensity.The Rho Termination Factor of Clostridium botulinum Contains a Prion-Like Domain with a Highly Amyloidogenic Core.The crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) provides the structural basis for its intrinsic activity and the short half-life of TAFIa.The Transcription Terminator Rho: A First Bacterial Prion.Discovery of Mechanism-Based Inactivators for Human Pancreatic Carboxypeptidase A from a Focused Synthetic Library.The Disordered C-Terminus of Yeast Hsf1 Contains a Cryptic Low-Complexity Amyloidogenic Region.Discovering Putative Prion-Like Proteins in : A Computational and Experimental AnalysisA pyrene-inhibitor fluorescent probe with large Stokes shift for the staining of Aβ, α-synuclein, and amylin amyloid fibrils as well as amyloid-containing Staphylococcus aureus biofilmsCharacterization of Human Prion-Like Proteins: Beyond Neurological DiseasesFormation of Cross-Beta Supersecondary Structure by Soft-Amyloid Cores: Strategies for Their Prediction and Characterization
P50
Q24815235-41CE0F5F-DB59-46BC-8102-2EC6F446D94EQ27651752-E0339208-9671-40ED-8E32-AD1B758B1AE2Q27657663-F12F6D51-BECE-4AED-A3C6-B63ED126D50AQ27686974-2B76938B-E4DE-460E-BCE4-49B3052C4267Q30163872-ECD78BC7-790C-4913-B14D-FF3B77D2E185Q30365734-5E2F008A-FDD6-4B24-A269-21CF7EE35892Q36615637-B6E9012B-A9F9-4ED2-AF4C-5172B738E2DAQ37314742-52B6B197-C4A9-4E70-8CB6-1DAE8984CF6AQ38915018-61B9B4FD-02B7-4F62-8206-C852986B9C23Q39420309-6E838707-3057-4395-AC4A-FABB6480A067Q41773166-2C0FC357-DB18-476A-B9FE-51457D4786DAQ43154963-125F944F-CA1F-4943-BF67-5DE27ABFE788Q47221772-19AB95DE-202E-4AD0-82FC-FD4588AAFFB7Q50066125-09517AB3-03DC-468A-9849-2502B872347AQ55351373-22C33EFF-3649-404E-B930-149C1843C953Q56346105-5F7A1267-CA99-449F-839F-33EB76AA1486Q58559175-8656158F-2119-4951-BC70-EF91515EEC08Q64111825-288A7361-0BD1-4FEA-A316-3BB3B25902A6Q92837253-6BF83D95-BD78-483F-BF63-5EB8DF1FC976
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Irantzu Pallares
@ast
Irantzu Pallares
@en
Irantzu Pallares
@es
Irantzu Pallares
@nl
type
label
Irantzu Pallares
@ast
Irantzu Pallares
@en
Irantzu Pallares
@es
Irantzu Pallares
@nl
prefLabel
Irantzu Pallares
@ast
Irantzu Pallares
@en
Irantzu Pallares
@es
Irantzu Pallares
@nl
P214
P106
P1153
8915809900
P214
P31
P496
0000-0002-8205-2060
P7859
viaf-305864223